Lyra Therapeutics, Inc. (NASDAQ:LYRA) Receives $4.50 Consensus PT from Analysts
Shares of Lyra Therapeutics, Inc. (NASDAQ:LYRA – Get Free Report) have been assigned an average recommendation of “Hold” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has assigned a buy […]
Shares of Lyra Therapeutics, Inc. (NASDAQ:LYRA – Get Free Report) have been assigned an average recommendation of “Hold” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has assigned a buy […]
